Latin America Investor Daily
SEE OTHER BRANDS

Get your fresh news on finance and banking in Latin America

Latin America Investor Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Investor Daily.

Press releases published on May 12, 2025

GigaCloud Technology Inc Announces First Quarter Ended March 31, 2025 Financial Results

GigaCloud Technology Inc Announces First Quarter Ended March 31, 2025 Financial Results

EL MONTE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced financial results for the first …

Espey Mfg. & Electronics Corp. reports third quarter results

Espey Mfg. & Electronics Corp. reports third quarter results

SARATOGA SPRINGS, N.Y., May 12, 2025 (GLOBE NEWSWIRE) -- Espey Mfg. …

Carbon Revolution Secures Further Release of $5m Million from OIC and further $0.4 Million Reserve Release from Existing Lenders

Carbon Revolution Secures Further Release of $5m Million from OIC and further $0.4 Million Reserve Release from Existing Lenders

GEELONG, Australia, May 12, 2025 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that …

Akoya Biosciences Reports First Quarter 2025 Financial Results

Akoya Biosciences Reports First Quarter 2025 Financial Results

MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. “Akoya remained focused on operational …

Amplify Energy Announces First Quarter 2025 Results, Beta Development Update and Updated Full-Year 2025 Guidance

Amplify Energy Announces First Quarter 2025 Results, Beta Development Update and Updated Full-Year 2025 Guidance

HOUSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today its operating and financial results for the first quarter of 2025 and updated full-year 2025 guidance for the Company. …

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

Q1 revenue of $21.9 million, increasing 11% year-over-year Q1 gross profit increased 9% year-over-year to $13.3 million Increases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million …

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK

LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets …

Rapid7 Announces First Quarter 2025 Financial Results

Rapid7 Announces First Quarter 2025 Financial Results

Annualized recurring revenue (“ARR”) of $837 million, an increase of 4% year-over-year Total revenue of $210 million, up 3% year-over-year; Product subscriptions revenue of $204 million, up 4% year-over-year GAAP operating loss of $0.1 million; Non-GAAP …

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity Bolt is running a …

Phunware Reports First Quarter 2025 Financial Results

Phunware Reports First Quarter 2025 Financial Results

New Customer Launches Drive 40% Revenue Growth for Software Subscriptions and Services Strong Balance Sheet of $109.7 Million Powering R…

FRP Holdings, Inc. (NASDAQ: FRPH) Announces Results for the First Quarter Ended March 31, 2025

FRP Holdings, Inc. (NASDAQ: FRPH) Announces Results for the First Quarter Ended March 31, 2025

JACKSONVILLE, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FRP Holdings, Inc. (NASDAQ-FRPH) – FRP Holdings is a real estate asset developer and manager across three differing asset classes including Multifamily, Industrial and Commercial, and Mining and Royalty …

Hallador Energy Company Reports First Quarter 2025 Financial and Operating Results

Hallador Energy Company Reports First Quarter 2025 Financial and Operating Results

– Q1 Total Revenue up 6% YoY to $117.8 Million – – Q1 Net Income up Materially YoY to $10.0 Million or $0.23 Earnings per Share – – Q1 Operating Cash Flow up ~2x YoY to $38.4 Million – – Q1 Adjusted EBITDA up ~3x YoY to $19.3 Million – TERRE HAUTE, Ind., …

Gaia Reports First Quarter 2025 Results

Gaia Reports First Quarter 2025 Results

BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the first quarter and ended March 31, 2025. Highlights: Fifth consecutive quarter of double digit increases …

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152, …

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2  …

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …

TPI Composites, Inc. Announces First Quarter 2025 Earnings Results – Operational Execution and Strategic Initiatives Drive Improved Financial Results; Initiation of Strategic Review

TPI Composites, Inc. Announces First Quarter 2025 Earnings Results – Operational Execution and Strategic Initiatives Drive Improved Financial Results; Initiation of Strategic Review

SCOTTSDALE, Ariz., May 12, 2025 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (Nasdaq: TPIC), today reported financial results for the first quarter ended March 31, 2025. TPI further announced that its Board of Directors has initiated a strategic review of the …

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 million Transaction …

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial …

MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended March 31, 2025

MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended March 31, 2025

Results for the Quarter Ended March 31, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.37 Net asset value per share as of the end of the quarter was $14.93, compared to $14.98 as of December 31, 2024, a decrease of …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service